a 68930

A 68930 is a potent and selective **dopamine D1-like receptor agonist**, primarily targeting D1 and D5 dopamine receptors. It exhibits high selectivity for D1-like over D2-like receptors (EC50 values approximately 2.1–2.5 nM for D1 and over 3900 nM for D2)[1][2][4]. Developed as a CNS-active **small molecule** for research use, A 68930 has shown activities including modulation of behavioral responses, neuroprotection, inhibition of inflammation (notably via NLRP3 inflammasome suppression), and promotion of epithelial repair in several preclinical models[3][5]. It was initially developed by Abbott Laboratories, mainly for potential applications in neurological and cardiovascular diseases, as well as research into dopaminergic signaling[5]. The drug has extremely limited or no clinical development, with its highest R&D status listed as "discontinued"[5].

Other names

A 68930 hydrochlorideA68930 hydrochlorideA-68930 hydrochloridecis-(±)-1-(aminomethyl)-3,4-dihydro-3-phenyl-1H-2-benzopyran-5,6-diol hydrochloride